New Delhi, Oct. 28 -- Artificial intelligence company Anthropic said its Claude model generated around 35,000 antibody designs in about a month for a potential food allergy treatment, as it expands efforts to use AI across drug discovery, manufacturing and clinical development.

In an update on its life sciences research, Anthropic said its work with biotechnology company Divergence Labs produced early results for a proposed treatment designed to remove immunoglobulin E (IgE), a molecule involved in allergic reactions, from immune cells. The approach aims to go beyond standard medications that neutralise IgE circulating in the blood.

Divergence Labs identified three designs that could bind to IgE and 20 that could dislodge it from immune...